An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Inclusion Criteria:

histologically or cytologically proven diagnosis of malignancy other than NSCLC
positive for translocation or inversion event involving the ALK gene locus
positive for ALK amplification events
positive for ALK activating point mutations

Exclusion Criteria:

mutations of amplifications involving the c-Met gene but not the ALK gene
concurrent treatment on another therapeutic clinical trial
prior therapy specifically directed against ALK